{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:05:02Z","timestamp":1787317502499,"version":"build-2736575974"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Khondrion B.V."},{"name":"European Innovation Council Horizon Europe","award":["830115 \u2013 KHON2bTREAT"],"award-info":[{"award-number":["830115 \u2013 KHON2bTREAT"]}]},{"name":"Energy4all"},{"name":"Join4Energy"},{"name":"Ride4Kids"},{"name":"Tim Foundation"},{"name":"Road4Energy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mitochondrial disease incorporates a group of rare conditions with no approved treatment to date, except for Leber hereditary optic neuropathy. Therapeutic options to alleviate the symptoms of mitochondrial disease are urgently needed. Sonlicromanol is a promising candidate, as it positively alters the key metabolic and inflammatory pathways associated with mitochondrial disease. Sonlicromanol is a reductive and oxidative distress modulator, selectively inhibiting microsomal prostaglandin E1 synthase activity. This phase 2b program, aimed at evaluating sonlicromanol in adults with m.3243A&amp;gt;G mutation and primary mitochondrial disease, consisted of a randomized controlled (RCT) study (dose-selection) followed by a 52-week open-label extension study (EXT, long-term tolerability, safety and efficacy of sonlicromanol).<\/jats:p>\n                  <jats:p>Patients were randomized (1:1:1) to receive 100 or 50 mg sonlicromanol or placebo twice daily (bid) for 28\u2005days with a \u22652-week wash-out period between treatments. Patients who completed the RCT study entered the EXT study, wherein they received 100 mg sonlicromanol bid.<\/jats:p>\n                  <jats:p>Overall, 27 patients were randomized (24 RCT patients completed all periods). Fifteen patients entered the EXT, and 12 patients were included in the EXT analysis set. All patients reported good tolerability and favourable safety, with pharmacokinetic results comparable to the earlier phase 2a study.<\/jats:p>\n                  <jats:p>The RCT primary end point [change from placebo in the attentional domain of the cognition score (visual identification; Cogstate IDN)] did not reach statistical significance. Using a categorization of the subject's period baseline a treatment effect over placebo was observed if their baseline was more affected (P = 0.0338). Using this approach, there were signals of improvements over placebo in at least one dose in the Beck Depression Inventory (BDI, P = 0.0143), Cognitive Failure Questionnaire (P = 0.0113) and the depression subscale of the Hospital Anxiety and Depression Scale (P = 0.0256).<\/jats:p>\n                  <jats:p>Statistically and\/or clinically meaningful improvements were observed in the patient- and clinician-reported outcome measures at the end of the EXT study [Test of Attentional Performance (TAP) with alarm, P = 0.0102; TAP without alarm, P = 0.0047; BDI somatic, P = 0.0261; BDI total, P = 0.0563; SF12 physical component score, P = 0.0008]. Seven of nine domains of RAND-Short Form-36-like SF-36 pain improved (P = 0.0105). Other promising results were observed in the Neuro-Quality of Life Short Form-Fatigue Scale (P = 0.0036), mini-Balance Evaluation Systems test (P = 0.0009), McGill Pain Questionnaire (P = 0.0105), EuroQol EQ-5D-5L-Visual Analog Scale (P = 0.0213) and EQ-5D-5L-Index (P = 0.0173). Most patients showed improvement in the Five Times Sit-To-Stand Test.<\/jats:p>\n                  <jats:p>Sonlicromanol was well-tolerated and demonstrated a favourable benefit\/risk ratio for up to 1 year. Sonlicromanol was efficacious in patients when affected at baseline, as seen across a variety of clinically relevant domains. Long-term treatment showed more pronounced changes from baseline.<\/jats:p>","DOI":"10.1093\/brain\/awae277","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:23:35Z","timestamp":1724876615000},"page":"896-907","source":"Crossref","is-referenced-by-count":20,"title":["Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A&amp;gt;G mutation"],"prefix":"10.1093","volume":"148","author":[{"given":"Jan","family":"Smeitink","sequence":"first","affiliation":[{"name":"Khondrion B.V. , 6534 AT Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Just","family":"van Es","sequence":"additional","affiliation":[{"name":"Certara Netherlands B.V. , 5349 AB Oss ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bosman","sequence":"additional","affiliation":[{"name":"Khondrion B.V. , 6534 AT Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirian C H","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center , 6525 GA Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Klopstock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , 80336 Munich ,","place":["Germany"]},{"name":"German Center for Neurodegenerative Diseases (DZNE) , 81377 Munich ,","place":["Germany"]},{"name":"Munich Cluster for Systems Neurology , 81377 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grainne","family":"Gorman","sequence":"additional","affiliation":[{"name":"Highly Specialised Service for Mitochondrial Disorders of Adults and Children, Newcastle upon Tyne Hospitals NHS Foundation Trust (OP) and Wellcome Centre for Mitochondrial Research, Newcastle University , NE2 4HH Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vissing","sequence":"additional","affiliation":[{"name":"Rigshospitalet, University of Copenhagen , DK-2100 Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerrit","family":"Ruiterkamp","sequence":"additional","affiliation":[{"name":"Khondrion B.V. , 6534 AT Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J","family":"Edgar","sequence":"additional","affiliation":[{"name":"Cogstate Ltd , SE1 4PG London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evertine J","family":"Abbink","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center , 6525 GA Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"van Maanen","sequence":"additional","affiliation":[{"name":"Khondrion B.V. , 6534 AT Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Pogoryelova","sequence":"additional","affiliation":[{"name":"Highly Specialised Service for Mitochondrial Disorders of Adults and Children, Newcastle upon Tyne Hospitals NHS Foundation Trust (OP) and Wellcome Centre for Mitochondrial Research, Newcastle University , NE2 4HH Newcastle upon Tyne ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Stendel","sequence":"additional","affiliation":[{"name":"Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , 80336 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almut","family":"Bischoff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , 80336 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Karin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Friedrich-Baur-Institute, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen , 80336 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Munshi","sequence":"additional","affiliation":[{"name":"Certara Netherlands B.V. , 5349 AB Oss ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"K\u00fcmmel","sequence":"additional","affiliation":[{"name":"IntiQuan AG , 4051 Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Burgert","sequence":"additional","affiliation":[{"name":"IntiQuan AG , 4051 Basel ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christianne","family":"Verhaak","sequence":"additional","affiliation":[{"name":"Department of Psychology, Radboud University Medical Center , 6525 GA Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herma","family":"Renkema","sequence":"additional","affiliation":[{"name":"Khondrion B.V. , 6534 AT Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"2025030619375800700_awae277-B1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/348651a0","article-title":"A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies","volume":"348","author":"Goto","year":"1990","journal-title":"Nature"},{"key":"2025030619375800700_awae277-B2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMra1012478","article-title":"Monogenic mitochondrial disorders","volume":"366","author":"Koopman","year":"2012","journal-title":"N Engl J Med"},{"key":"2025030619375800700_awae277-B3","doi-asserted-by":"crossref","first-page":"16080","DOI":"10.1038\/nrdp.2016.80","article-title":"Mitochondrial diseases","volume":"2","author":"Gorman","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025030619375800700_awae277-B4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.410160409","article-title":"Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome","volume":"16","author":"Pavlakis","year":"1984","journal-title":"Ann Neurol"},{"key":"2025030619375800700_awae277-B5","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1002\/mus.880181425","article-title":"Maternally inherited diabetes and deafness (MIDD): A distinct subtype of diabetes associated with a mitochondrial tRNA(Leu)(UUR) gene point mutation","volume":"3","author":"van den Ouweland","year":"1995","journal-title":"Muscle Nerve Suppl"},{"key":"2025030619375800700_awae277-B6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11306-020-01769-w","article-title":"One mutation, three phenotypes: Novel metabolic insights on MELAS, MIDD, and myopathy caused by the m.3243A &gt; G mutation","volume":"17","author":"Esterhuizen","year":"2021","journal-title":"Metabolomics"},{"key":"2025030619375800700_awae277-B7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ana.21328","article-title":"Muscle 3243A--&gt;G mutation load and capacity of the mitochondrial energy-generating system","volume":"63","author":"Janssen","year":"2008","journal-title":"Ann Neurol"},{"key":"2025030619375800700_awae277-B8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/1873-3468.14049","article-title":"The molecular pathology of pathogenic mitochondrial tRNA variants","volume":"595","author":"Richter","year":"2021","journal-title":"FEBS Lett"},{"key":"2025030619375800700_awae277-B9","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tcb.2021.10.005","article-title":"Rewiring cell signaling pathways in pathogenic mtDNA mutations","volume":"32","author":"Chung","year":"2022","journal-title":"Trends Cell Biol"},{"key":"2025030619375800700_awae277-B10","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41598-020-79466-w","article-title":"Mechanism of action and potential applications of selective inhibition of microsomal prostaglandin E synthase-1-mediated PGE(2) biosynthesis by sonlicromanol\u2019s metabolite KH176m","volume":"11","author":"Jiang","year":"2021","journal-title":"Sci Rep"},{"key":"2025030619375800700_awae277-B11","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1038\/s41598-018-24900-3","article-title":"KH176 safeguards mitochondrial diseased cells from redox stress-induced cell death by interacting with the thioredoxin system\/peroxiredoxin enzyme machinery","volume":"8","author":"Beyrath","year":"2018","journal-title":"Sci Rep"},{"key":"2025030619375800700_awae277-B12","doi-asserted-by":"crossref","first-page":"11733","DOI":"10.1038\/s41598-017-09417-5","article-title":"Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh disease","volume":"7","author":"de Haas","year":"2017","journal-title":"Sci Rep"},{"key":"2025030619375800700_awae277-B13","doi-asserted-by":"crossref","first-page":"165727","DOI":"10.1016\/j.bbadis.2020.165727","article-title":"Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice","volume":"1866","author":"Frambach","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2025030619375800700_awae277-B14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.stemcr.2021.07.002","article-title":"Sonlicromanol improves neuronal network dysfunction and transcriptome changes linked to m.3243A&gt;G heteroplasmy in iPSC-derived neurons","volume":"16","author":"Klein Gunnewiek","year":"2021","journal-title":"Stem Cell Reports"},{"key":"2025030619375800700_awae277-B15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.1197","article-title":"The KHENERGY study: Safety and efficacy of KH176 in mitochondrial m.3243A&gt;G spectrum disorders","volume":"105","author":"Janssen","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2025030619375800700_awae277-B16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s13023-017-0715-0","article-title":"KH176 under development for rare mitochondrial disease: A first-in-man randomized controlled clinical trial in healthy male volunteers","volume":"12","author":"Koene","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2025030619375800700_awae277-B17"},{"key":"2025030619375800700_awae277-B18","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/acn3.532","article-title":"Phenotypic heterogeneity in m. A&gt;G mitochondrial disease: The role of nuclear factors","volume":"5","author":"Pickett","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"2025030619375800700_awae277-B19","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1176\/jnp.17.1.98","article-title":"Self-administered screening for mild cognitive impairment: Initial validation of a computerized test battery","volume":"17","author":"Tornatore","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2025030619375800700_awae277-B20","first-page":"124","volume-title":"Applied neuropsychology of attention","author":"Zimmermann","year":"2004"},{"key":"2025030619375800700_awae277-B21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"2025030619375800700_awae277-B22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","article-title":"Comparison of beck depression inventories\u2014IA and II in psychiatric outpatients","volume":"67","author":"Beck","year":"1996","journal-title":"J Personality Assessment"},{"key":"2025030619375800700_awae277-B23","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1212\/01.wnl.0000219759.72195.41","article-title":"Mitochondrial disease in adults: A scale to monitor progression and treatment","volume":"66","author":"Schaefer","year":"2006","journal-title":"Neurology"},{"key":"2025030619375800700_awae277-B24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/0031-9384(84)90269-5","article-title":"Development of the university of Pennsylvania smell identification test: A standardized microencapsulated test of olfactory function","volume":"32","author":"Doty","year":"1984","journal-title":"Physiol Behav"},{"key":"2025030619375800700_awae277-B25","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","article-title":"Neuro-QOL: Brief measures of health-related quality of life for clinical research in neurology","volume":"78","author":"Cella","year":"2012","journal-title":"Neurology"},{"key":"2025030619375800700_awae277-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2044-8260.1982.tb01421.x","article-title":"The cognitive failures questionnaire (CFQ) and its correlates","volume":"21","author":"Broadbent","year":"1982","journal-title":"Br J Clin Psychol"},{"key":"2025030619375800700_awae277-B27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/ptj\/85.10.1034","article-title":"Clinical measurement of sit-to-stand performance in people with balance disorders: Validity of data for the five-times-sit-to-stand test","volume":"85","author":"Whitney","year":"2005","journal-title":"Phys Ther"},{"key":"2025030619375800700_awae277-B28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/16501977-0537","article-title":"Using psychometric techniques to improve the balance evaluation system\u2019s test: The mini-BESTest","volume":"42","author":"Franchignoni","year":"2010","journal-title":"J Rehabil Med"},{"key":"2025030619375800700_awae277-B29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jphys.2015.04.002","article-title":"The mini-balance evaluation systems test (mini-BESTest)","volume":"61","author":"Potter","year":"2015","journal-title":"J Physiother"},{"key":"2025030619375800700_awae277-B30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form McGill pain questionnaire","volume":"30","author":"Melzack","year":"1987","journal-title":"Pain"},{"key":"2025030619375800700_awae277-B31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection","volume":"6","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2025030619375800700_awae277-B32","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"2025030619375800700_awae277-B33","author":"Sasinowski"},{"key":"2025030619375800700_awae277-B34","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jclinepi.2016.11.016","article-title":"The minimal clinically important difference raised the significance of outcome effects above the statistical level, with methodological implications for future studies","volume":"82","author":"Angst","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2025030619375800700_awae277-B35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"2025030619375800700_awae277-B36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/VES-2006-164-510","article-title":"The five times to stand test: Responsiveness to change and concurrent validity in adults undergoing vestibular rehabilitation","volume":"16","author":"Meretta","year":"2006","journal-title":"J Vestib Res"},{"key":"2025030619375800700_awae277-B37","doi-asserted-by":"crossref","first-page":"102784","DOI":"10.1016\/j.ebiom.2020.102784","article-title":"Genetics of mitochondrial diseases: Identifying mutations to help diagnosis","volume":"56","author":"Stenton","year":"2020","journal-title":"EBioMedicine"},{"key":"2025030619375800700_awae277-B38","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1212\/WNL.0000000000207402","article-title":"Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: The MMPOWER-3 randomized clinical trial","volume":"101","author":"Karaa","year":"2023","journal-title":"Neurology"},{"key":"2025030619375800700_awae277-B39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s41687-022-00534-y","article-title":"Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease","volume":"6","author":"Gwaltney","year":"2022","journal-title":"J Patient Rep Outcomes"},{"key":"2025030619375800700_awae277-B40","doi-asserted-by":"crossref","first-page":"e687","DOI":"10.1212\/WNL.0000000000008861","article-title":"Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial","volume":"94","author":"Madsen","year":"2020","journal-title":"Neurology"},{"key":"2025030619375800700_awae277-B41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/jmedgenet-2019-106800","article-title":"Six-year prospective follow-up study in 151 carriers of the mitochondrial DNA 3243 A&gt;G variant","volume":"58","author":"de Laat","year":"2021","journal-title":"J Med Genet"},{"key":"2025030619375800700_awae277-B42","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1007\/s00415-022-11324-3","article-title":"Primary mitochondrial myopathy: 12-month follow-up results of an Italian cohort","volume":"269","author":"Montano","year":"2022","journal-title":"J Neurol"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awae277\/60439835\/awae277.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/3\/896\/60439835\/awae277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/3\/896\/60439835\/awae277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T14:45:31Z","timestamp":1741272331000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/3\/896\/7877163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,11,6]]},"published-print":{"date-parts":[[2025,3,6]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awae277","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,11,6]]}}}